Two years of Imaavy (nipocalimab) delivers sustained gains for teen myasthenia gravis patients. New data from the Vibrance-MG trial show adolescents with generalized myasthenia gravis (gMG) maintained meaningful improvements in daily function and muscle strength over 108 weeks. Some patients were also able to reduce or discontinue corticosteroids entirely.
Two years of Imaavy keeps teen myasthenia gravis patients stronger
New two-year data from the phase 2/3 Vibrance-MG study offer encouraging news for adolescents living with generalized myasthenia gravis (gMG). Seven patients aged 12–17 with antibody-positive gMG who hadn't responded adequately to standard therapy were treated with nipocalimab (Imaavy), and the results held up well over time — with sustained gains in both daily functioning and muscle strength at the 108-week mark.
Perhaps just as notable: of the six participants who were on corticosteroids at the start of the study, three managed to reduce their dose and one stopped altogether by the two-year point — a meaningful development given the long-term side effects associated with steroid use in young patients. No new safety signals were identified over the course of treatment.
By the Numbers
Why it matters: Myasthenia gravis is rare in adolescents, and long-term treatment data in this age group are scarce. These findings suggest nipocalimab may offer durable disease control with a steroid-sparing benefit — though the small, open-label cohort of just seven patients means larger studies are needed before drawing firm conclusions.
